Incyte Corporation's executive vice president sold 3,680 shares, reducing their ownership by 5.96%, now holding 58,042 shares valued at approximately $4.62 million. Institutional investors control 96.97% of the stock, with recent hedge fund activity indicating significant interest. UBS Group initiated coverage with a "neutral" rating and a $77 price target, suggesting an 11.30% upside.